Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Holding IMCR?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.23Last Year’s EPS
-$0.4Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -14.14%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance and growth in the U.S. market for KIMMTRAK, along with significant advancements in the clinical pipeline. However, challenges in the European market due to reimbursement issues and a stable net loss were noted as concerns.Company Guidance
During the Immunocore Q2 2024 earnings call, the company provided several key metrics and strategic updates. KIMMTRAK achieved $146 million in net sales for the first half of 2024, marking a 34% increase compared to the previous year, with a significant 11% revenue growth in the U.S. during Q2. KIMMTRAK, launched in 19 countries with new launches in Poland and Sweden, is anticipated to expand further with the TEBE-AM and ATOM trials potentially benefiting up to 6,000 patients. The company also advanced nine clinical programs, including a Phase III trial for brenetafusp in melanoma and a promising HIV program aiming for a functional cure. Financially, Q2 net sales reached $75.3 million, a 7% increase from Q1, despite a challenging European reimbursement environment. The company's robust pipeline and strategic focus position it for continued growth, leveraging its strong balance sheet and innovative research.KIMMTRAK Strong Performance
KIMMTRAK achieved $146 million in net sales for the first half of 2024, a 34% increase compared to the same period last year. This growth was driven by strong U.S. performance and increased market penetration.
Pipeline Advancements
Progression of 9 clinical programs, including the start of a Phase III trial for brenetafusp in first-line cutaneous melanoma. Upcoming data presentations at ESMO and in Q4 for ovarian and lung cancer.
Financial Position
Net cash and marketable securities increased to $860 million as of June 30, 2024. The U.S. market contributed over 70% of global net sales.
---
IMCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IMCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $32.99 | $33.51 | +1.58% |
| Aug 08, 2024 | $36.90 | $37.92 | +2.76% |
| May 08, 2024 | $61.04 | $61.32 | +0.46% |
| Feb 28, 2024 | $70.45 | $69.21 | -1.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Immunocore Holdings (IMCR) report earnings?
Immunocore Holdings (IMCR) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Immunocore Holdings (IMCR) earnings time?
Immunocore Holdings (IMCR) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMCR EPS forecast?
IMCR EPS forecast for the fiscal quarter 2024 (Q4) is -$0.23.
---